Pharma has long marketed opioids in ways that contribute to opioid use disorder and deaths by overdose. Regulatory mistakes in approving and labeling new analgesics by the FDA didn’t make us safer.
AMA J Ethics. 2020;22(8):E743-750. doi:
10.1001/amajethics.2020.743.
Leah M. Marcotte, MD, Jeffrey Krimmel-Morrison, MD, and Joshua M. Liao, MD, MSc
Individuals can underperform in circumstances of shared accountability. In clinical settings, this is an unintended consequence of the health care sector’s complexity fragmentation.
AMA J Ethics. 2020;22(9):E802-807. doi:
10.1001/amajethics.2020.802.
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Aminu Yakubu, Nchangwi Syntia Munung, and Jantina De Vries, PhD
African cancer research is embedded in underresourced health care infrastructures, illuminating ethical questions about benefit sharing and governance.
AMA J Ethics. 2020;22(2):E156-163. doi:
10.1001/amajethics.2020.156.
As larger organizations become more influential in the health care sector, the Code can help physicians navigate those organizations’ influence on their practices.
AMA J Ethics. 2020;22(3):E217-220. doi:
10.1001/amajethics.2020.217.
Upcoding and misrepresenting clinical information constitute fraud, cost a lot, and can result in patient harm and unnecessary procedures and prescriptions.
AMA J Ethics. 2020;22(3):E221-231. doi:
10.1001/amajethics.2020.221.
Corporatization in health care has complicated clinicians’ and organizations’ efforts to balance interests of individual patients against an organization’s bottom line.
AMA J Ethics. 2020;22(3):E187-192. doi:
10.1001/amajethics.2020.187.